Baseline characteristics of study population
| Characteristic . | ASA (n = 176) . | LMWH (n = 166) . |
|---|---|---|
| Median age at diagnosis, y (IQR) | 57 (51-61) | 58 (52-62) |
| Age, y, n (%) | ||
| 31-40 | 4 (2) | 2 (1) |
| 41-50 | 35 (20) | 29 (17) |
| 51-60 | 74 (42) | 69 (42) |
| ≥ 60 | 63 (36) | 66 (40) |
| Sex, n (%) | ||
| Male | 87 (49) | 99 (60) |
| Multiple myeloma treatment, n (%) | ||
| Rd | 176 (100) | 166 (100) |
| MPR | 85 (48) | 80 (48) |
| Mel200 | 91 (52) | 86 (52) |
| International Staging System stage, n (%) | ||
| I | 75 (43) | 90 (54) |
| II | 55 (31) | 45 (27) |
| III | 46 (26) | 31 (19) |
| Median creatinine level, mg/dL (IQR) | 0.9 (0.76-1.13) | 0.9 (0.8-1.1) |
| Median glycemia level, mg/dL (IQR) | 93 (84-103) | 94 (88-105) |
| Karnofsky performance status score, n (%) | ||
| ≤ 70 | 27 (15) | 23 (14) |
| Data missing | 0 | 1 (1) |
| Risk factors, n (%)* | ||
| Diabetes | 2 (1) | 2 (1) |
| Cardiovascular disease | 12 (7) | 6 (4) |
| Hypertension | 12 (7) | 6 (4) |
| Coronary arterial disease | 0 | 1 (1) |
| Dyslipidemia | 3 (2) | 0 |
| Orthopedic surgery | 0 | 0 |
| Prior thromboembolism | 0 | 0 |
| Inherited coagulopathies | 0 | 0 |
| Recombinant human erythropoietin | 30 (17) | 28 (17) |
| ≥ 2 risk factors | 4 (2) | 2 (1) |
| Characteristic . | ASA (n = 176) . | LMWH (n = 166) . |
|---|---|---|
| Median age at diagnosis, y (IQR) | 57 (51-61) | 58 (52-62) |
| Age, y, n (%) | ||
| 31-40 | 4 (2) | 2 (1) |
| 41-50 | 35 (20) | 29 (17) |
| 51-60 | 74 (42) | 69 (42) |
| ≥ 60 | 63 (36) | 66 (40) |
| Sex, n (%) | ||
| Male | 87 (49) | 99 (60) |
| Multiple myeloma treatment, n (%) | ||
| Rd | 176 (100) | 166 (100) |
| MPR | 85 (48) | 80 (48) |
| Mel200 | 91 (52) | 86 (52) |
| International Staging System stage, n (%) | ||
| I | 75 (43) | 90 (54) |
| II | 55 (31) | 45 (27) |
| III | 46 (26) | 31 (19) |
| Median creatinine level, mg/dL (IQR) | 0.9 (0.76-1.13) | 0.9 (0.8-1.1) |
| Median glycemia level, mg/dL (IQR) | 93 (84-103) | 94 (88-105) |
| Karnofsky performance status score, n (%) | ||
| ≤ 70 | 27 (15) | 23 (14) |
| Data missing | 0 | 1 (1) |
| Risk factors, n (%)* | ||
| Diabetes | 2 (1) | 2 (1) |
| Cardiovascular disease | 12 (7) | 6 (4) |
| Hypertension | 12 (7) | 6 (4) |
| Coronary arterial disease | 0 | 1 (1) |
| Dyslipidemia | 3 (2) | 0 |
| Orthopedic surgery | 0 | 0 |
| Prior thromboembolism | 0 | 0 |
| Inherited coagulopathies | 0 | 0 |
| Recombinant human erythropoietin | 30 (17) | 28 (17) |
| ≥ 2 risk factors | 4 (2) | 2 (1) |
ASA indicates aspirin; LMWH, low-molecular-weight heparin; IQR, interquartile range; Rd, lenalidomide and low-dose dexamethasone; MPR, melphalan, prednisone plus lenalidomide; and Mel200, melphalan as conditioning regimen for autologous stem cell transplantation.
Risk factors include diabetes, cardiovascular disease, orthopedic surgery during the past 3 months, dyslipidemia, prior thromboembolism in the medical history, inherited coagulopathies, concomitant recombinant human erythropoietin administration.